Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details)

v3.3.1.900
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Deferred tax assets      
Net operating loss carryforwards $ 276,740 $ 268,400  
Orphan drug and research and development expenses 36,387 31,735  
Deferred compensation 1,761 20,312  
Capitalized research and development expenses 22,647 28,408  
Other, net 4,966 7,876  
Total deferred tax assets 342,501 356,731  
Valuation allowance $ (342,501) $ (356,731)  
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent) (34.00%) (34.00%) (34.00%)
Valuation allowance (as a percent) 31.30% 32.30% 37.90%
Other, net (as a percent) 2.70% 1.70% (3.90%)
Effective tax rate (as a percent) 0.00% 0.00% 0.00%